(Q37003558)

English

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

scientific article published on 04 September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 August 2017

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells (English)

1 reference

Europe PubMed Central

17 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

15

object named as

Guido Marcucci

1 reference

Europe PubMed Central

17 August 2017

20

object named as

John C Byrd

1 reference

Europe PubMed Central

17 August 2017

9

object named as

William Blum

1 reference

Europe PubMed Central

17 August 2017

Natarajan Muthusamy

19

object named as

Natarajan Muthusamy

1 reference

Europe PubMed Central

17 August 2017

Leslie A Andritsos

10

object named as

Leslie Andritsos

1 reference

Europe PubMed Central

17 August 2017

Gerard Lozanski

6

object named as

Gerard Lozanski

1 reference

Europe PubMed Central

17 August 2017

Shih-Ching Chen

13

object named as

Ching-Shih Chen

1 reference

Europe PubMed Central

17 August 2017

7

object named as

Asha Ramanunni

1 reference

Europe PubMed Central

17 August 2017

Rosa Lapalombella

1

object named as

Rosa Lapalombella

1 reference

Europe PubMed Central

17 August 2017

12

object named as

Amy Lehman

1 reference

Europe PubMed Central

17 August 2017

author name string

Bo Yu

2

1 reference

Europe PubMed Central

17 August 2017

Georgia Triantafillou

3

1 reference

Europe PubMed Central

17 August 2017

Qing Liu

4

1 reference

Europe PubMed Central

17 August 2017

Jonathan P Butchar

5

1 reference

Europe PubMed Central

17 August 2017

Lisa L Smith

8

1 reference

Europe PubMed Central

17 August 2017

Da-Sheng Wang

11

1 reference

Europe PubMed Central

17 August 2017

Amy J Johnson

14

1 reference

Europe PubMed Central

17 August 2017

Robert J Lee

16

1 reference

Europe PubMed Central

17 August 2017

L James Lee

17

1 reference

Europe PubMed Central

17 August 2017

Susheela Tridandapani

18

1 reference

Europe PubMed Central

17 August 2017

language of work or name

0 references

publication date

4 September 2008

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

112

1 reference

Europe PubMed Central

17 August 2017

5180-5189

1 reference

Europe PubMed Central

17 August 2017

13

1 reference

Europe PubMed Central

17 August 2017

Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Immunomodulating drugs for chronic lymphocytic leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Antibody therapy for chronic lymphocytic leukemia: a promising new modality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Protein G: a powerful tool for binding and detection of monoclonal and polyclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Expression of the human B-cell surface protein CD20: alteration by phorbol 12-myristate 13-acetate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

29 September 2017

Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

4 September 2018

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

4 September 2018

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2597613

4 September 2018

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Down-regulation of CD20 on B cells upon CD40 activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decreased antibody-dependent cellular cytotoxicity in various types of leukaemia in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A physicochemical study of protein G, a molecule with unique immunoglobulin G-binding properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group fo

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18772452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2008-01-133108

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37003558&oldid=2139822968"